China National Pharmaceutical Group (Sinopharm) said on Thursday that it has inoculated nearly a million people with its vaccine in the country.
"In terms of emergency use, the vaccines were applied to almost a million people and there has not been a single case of a serious adverse event".
China initiated the emergency use program in July.
China has been giving experimental Covid-19 vaccines to people including state employees, global students, and essential workers heading overseas since July.
Two vaccine candidates are developed by Sinopharm's subsidiary China National Biotec Group (CNBG), and the third is developed by Sinovac Biotech. The data from an emergency program is inefficient and unable to determine a vaccine's effectiveness.
"In terms of emergency use, the vaccines were applied to almost a million people and there has not been a single case of a serious adverse event".Читайте также: Laliga Hails Chukwueze’s Impact In Villarreal’s Draw Vs Real Madrid
Late-stage, or Phase III, trials are ongoing to confirm the findings, researchers said, and to test whether the vaccine protects against infection with SARS-CoV-2 in a broad range of people, including people with underlying health conditions. "A total of 40,000 people will participate in this trial in 7 countries, of which 8 to 10, 000 will be Pakistani", he said.
"Until now, all our progress, from research to clinical trials to production and emergency use, we have been leading the world", Jingzhen continued.
AstraZeneca and Oxford University's potential COVID-19 vaccine produced a strong immune response in older adults, data published on Thursday showed, with researchers expecting to release late-stage trial results by Christmas.
The Chinese company has not yet provided any clear clinical evidence of efficacy. On Wednesday, Pfizer said that its vaccine is 94.5 percent effective even among the elderly and has no side effects.
Unlike the Pfizer-BioNTech and Moderna shots, both of which use new technology known as messenger RNA, AstraZeneca's is a viral vector vaccine made from a weakened version of a common cold virus found in chimpanzees.
Sinopharm didn't respond to Newsweek's request for comment in time for publication.При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2021 Copyright.
Автоматизированное извлечение информации сайта запрещено.
Код для вставки в блог